| Literature DB >> 23788850 |
Tomasz Piotrowski1, Małgorzata Skórska, Agata Jodda, Adam Ryczkowski, Joanna Kaźmierska, Krystyna Adamska, Aldona Karczewska-Dzionk, Małgorzata Zmijewska-Tomczak, Hanna Włodarczyk.
Abstract
AIM OF THE STUDY: Helical tomotherapy is one of the methods of radiotherapy. This method enables treatment implementation for a wide spectrum of clinical cases. The vast array of therapeutic uses of helical tomotherapy results directly from the method of dose delivery, which is significantly different from the classic method developed for conventional linear accelerators. The paper discusses the method of dose delivery by a tomotherapy machine. Moreover, an analysis and presentation of treatment plans was performed in order to show the therapeutic possibilities of the applied technology. Dose distributions were obtained for anaplastic medulloblastoma, multifocal metastases to brain, vulva cancer, tongue cancer, metastases to bones, and advanced skin cancer. Tomotherapy treatment plans were compared with conventional linear accelerator plans.Entities:
Keywords: IMRT; evaluation of the dose distribution; helical tomotherapy; treatment planning
Year: 2012 PMID: 23788850 PMCID: PMC3687380 DOI: 10.5114/wo.2012.27332
Source DB: PubMed Journal: Contemp Oncol (Pozn) ISSN: 1428-2526
Basic parameters used in the course of dose distribution planning for helical tomotherapy and conventional medical linear accelerator, for the following: 1 – anaplastic medulloblastoma, 2 – multifocal metastases to brain, 3 – vulva cancer, 4 – tongue cancer, 5 – metastases to bones, 6 – advanced skin cancer
| No of case | Helical tomotherapy (HT) | Conventional linear accelerator (CLA) | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 | 1 phase | 2 phase | 3 phase | 1 phase | 2 phase | 3 phase | ||
| FW: | 5 | 2.5 | 2.5 | Method: | 3 iso, 3DCRTc | 2 iso, 3DCRTc | 1 iso, 3DCRTc | |
| Pitch: | 0.287 | 0.287 | 0.287 | TNF: | 17 | 8 | 2 | |
| MF: | 2.1 | 2.2 | 2.3 | Energy: | 6 MV | 6 MV | 6 MV | |
| 2 | Simultaneus integrated boost | |||||||
| FW: | 2.5 | Method: | 1 isocentre, IMRT, noncoplanar | |||||
| Pitch: | 0.215 | TNF: | 13 | |||||
| MF: | 5.0 | Energy: | 6 MV | |||||
| 3 | FW: | 2.5 | Method: | 1 isocentre, IMRT, coplanar | ||||
| Pitch: | 0.287 | TNF: | 9 | |||||
| MF: | 2.4 | Energy: | 6 MV and 20 MV | |||||
| 4 | Simultaneus integrated boost | |||||||
| FW: | 2.5 | Method: | 1 isocentre, IMRT, noncoplanar | |||||
| Pitch: | 0.287 | TNF: | 7 | |||||
| MF: | 3.0 | Energy: | 6 MV | |||||
| 5 | FW: | 2.5 | Method: | 3 isocentres, IMRT, coplanar | ||||
| Pitch: | 0.215 | TNF: | 16 | |||||
| MF: | 2.7 | Energy: | 20 MV | |||||
| 6 | FW: | 1 | Method: | 1 isocentre, IMRT, noncoplanar | ||||
| Pitch: | 0.215 | TNF: | 6 | |||||
| MF: | 1.8 | Energy: | 6 MV | |||||
Dose normalization: median PTV volume for each cases receives at least 100% of the prescribed dose
FW – field width in cm
MF – modulation factor
TNF – total number of fields
IMRT – intensity modulated radiotherapy
3DCRT – three dimensional conformal radiotherapy realized by coplanar fields
for each case IMRT realized by sliding window technique using 120 multileaf collimator
Fig. 1Comparison of dose distributions on tomography scans for plans implemented using (a) conventional linear accelerator and (b) helical tomotherapy. Individual clinical cases have been marked with the following numbers: 1 – anaplastic medulloblastoma, 2 – multifocal metastases to brain, 3 – vulva cancer, 4 – tongue cancer, 5 – metastases to bones, 6 – advanced skin cancer
Time in seconds necessary for delivering fractional dose for helical tomotherapy and conventional medical linear accelerator, for the following: 1 – anaplastic medulloblastoma, 2 – multifocal metastases to brain, 3 – vulva cancer, 4 – tongue cancer, 5 – metastases to bones, 6 – advanced skin cancer
| No of case | Time of the fraction dose delivery [s] | |
|---|---|---|
|
| ||
| HT | CLA | |
| 1 | 646 | 878 |
| 602 | 350 | |
| 202 | 48 | |
| 2 | 542 | 1191 |
| 3 | 493 | 649 |
| 4 | 441 | 660 |
| 5 | 1480 | 1241 |
| 6 | 489 | 902 |
Fig. 2Differential histogram of dose distribution in planning target volume (PTV) of helical tomotherapy (blue line) and radiotherapy delivered by a conventional linear accelerator (red line) Clinical cases were marked as follows: 1 – anaplastic medulloblastoma, 2 – multifocal metastases to brain, 3 – vulva cancer, 4 – tongue cancer, 5 – metastases to bones, 6 – advanced skin cancer. Black line on each graph denotes expected value of therapeutic dose. The green area denotes overlapping part of the histograms for tomotherapy and a conventional linear accelerator, yellow area belongs only to the histogram for a conventional linear accelerator, and blue area belongs only to the histogram for tomotherapy
Comparison of the median dose and maximum dose in organ at risk for plans implemented using: (a) conventional linear accelerator and (b) helical tomotherapy. Clinical cases have been marked with the following numbers: 1 – anaplastic medulloblastoma, 2 – multifocal metastases to brain, 3 – vulva cancer, 4 – tongue cancer, 5 – metastases to bones, 6 – advanced skin cancer
| No of case | Dose [Gy] → Structure ↓ | Median | Maximum | ||
|---|---|---|---|---|---|
| HT | CLA | HT | CLA | ||
| 1 | Colchea R | 37.4 | 53.4 | 40.1 | 54.4 |
| Colchea L | 38.5 | 52.3 | 42.3 | 53.1 | |
| Pancreas | 8.3 | 12.4 | 13.4 | 27.1 | |
| Thyroid | 12.1 | 23.0 | 25.2 | 31.6 | |
| Pituitary | 45.3 | 43.7 | 49.3 | 48.9 | |
| Stomach | 6.6 | 8.8 | 13.0 | 20.4 | |
| Livier | 5.4 | 8.2 | 20.7 | 29.4 | |
| Lens R | 4.1 | 2.1 | 4.3 | 3.1 | |
| Lens L | 4.0 | 2.6 | 4.4 | 2.9 | |
| Parotid R | 17.2 | 44.2 | 36.2 | 55.3 | |
| Parotid L | 16.3 | 28.5 | 30.9 | 54.1 | |
| Spleen | 4.4 | 2.0 | 17.3 | 32.2 | |
| Heart | 6.6 | 10.0 | 25.8 | 38.6 | |
| Lungs | 5.8 | 11.0 | 32.3 | 41.4 | |
| Brainstem | 54.7 | 54.2 | 56.0 | 55.9 | |
| 2 | Eye R | 8.2 | 15.2 | 26.1 | 36.8 |
| Eye L | 8.0 | 12.1 | 28.0 | 36.4 | |
| Optic Nerve R | 34.8 | 35.4 | 43.8 | 36.7 | |
| Optic Nerve L | 33.7 | 35.4 | 43.5 | 36.7 | |
| Kidney R | 6.3 | 10.8 | 18.3 | 32.3 | |
| Kidney L | 6.0 | 9.1 | 15.1 | 29.9 | |
| Larynx | 8.1 | 28.1 | 24.7 | 32.6 | |
| Intestines | 6.4 | 8.2 | 35.2 | 34.6 | |
| Chiasma | 42.2 | 37.3 | 48.6 | 49.4 | |
| Eye R | 3.9 | 2.5 | 9.8 | 8.0 | |
| Eye L | 3.6 | 2.1 | 9.7 | 8.0 | |
| Optic Nerve R | 9.8 | 9.0 | 13.3 | 12.2 | |
| Optic Nerve L | 9.9 | 8.5 | 14.3 | 13.7 | |
| Lens R | 2.6 | 1.5 | 4.3 | 2.5 | |
| Lens L | 2.0 | 1.4 | 3.8 | 2.0 | |
| Chiasma | 9.8 | 10.0 | 12.1 | 11.8 | |
| 3 | Femoral Head L | 27.0 | 41.2 | 51.9 | 51.6 |
| Rectum | 22.1 | 24.5 | 51.1 | 52.0 | |
| Bladder | 33.0 | 25.4 | 53.0 | 54.6 | |
| Intestines | 24.9 | 26.4 | 52 | 55.0 | |
| Endoprosthesis | 6.8 | 12.1 | 44.0 | 44.1 | |
| 4 | Verbal Canal | 21.4 | 36.7 | 38.9 | 49.5 |
| Spinal Cord | 16.5 | 35.5 | 26.2 | 45.1 | |
| Parotid R | 20.7 | 25.0 | 57.8 | 59.9 | |
| Mandible | 45.2 | 49.1 | 68.2 | 66.8 | |
| Larynx | 28.2 | 26.7 | 64.6 | 63.6 | |
| Brainstem | 4.4 | 2.6 | 28.7 | 53.5 | |
| 5 | Kidney R | 1.3 | 0.3 | 5.8 | 4.6 |
| Kidney L | 1.3 | 0.3 | 6.0 | 5.7 | |
| Spinal Cord | 3.5 | 5.7 | 31.8 | 30.6 | |
| Intestines | 0.6 | 3.5 | 31.0 | 31.7 | |
| Bladder | 0.5 | 1.7 | 19.3 | 22.0 | |
| 6 | Lens R | 4.7 | 4.6 | 6.1 | 6.4 |
| Lens L | 12.8 | 31.6 | 19.1 | 33.2 | |
| Eye R | 9.7 | 6.3 | 25.7 | 28.3 | |
| Eye L | 27.7 | 36.4 | 56.8 | 56.9 | |
| Optic Nerve R | 28.7 | 25.7 | 36.9 | 36.5 | |
| Optic Nerve L | 45.2 | 48.0 | 53.7 | 53.3 | |
| Brainstem | 13.2 | 19.7 | 31.5 | 33.7 | |
| Chiasma | 28.0 | 33.2 | 38.3 | 41.1 | |
|
| |||||
| color codes legend: | |||||
| HT dose smaller than CLA dose about 5 Gy | |||||
| HT dose smaller than CLA dose about 2 Gy difference between HT and CLA dose smaller than 2 Gy | |||||
| HT dose higher than CLA dose about 2 Gy | |||||
| HT dose higher than CLA dose about 5 Gy | |||||
| HT – helical tomotherapy; CLA – conventional linear acceleretor; L – left; R – right | |||||
Fig. 3Tomography scans of the pelvis area with endoprosthesis taken by: a) computed tomography; b) helical tomography. In both cases the same imaging window was used